Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Quantum BioPharma Ltd. (QNTM)
Toronto, ON, CA
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
Based on only 1 article — low confidence
- Quantum BioPharma Provides Corporate Update GlobeNewsWire
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.69% | -3.62% | +43.34% | +38.63% | -39.26% | -30.68% | -44.52% | -92.86% | -95.28% | -99.55% | -99.55% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+35.1% ★ Q1'26: +60.4% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-3,302.6% Q1'26: +108.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+189.0% Q1'26: +294.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.07× Q1'26: -0.08× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. |
Dec 2028 1 Rev. Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
est: 924.3K (-100.0%)
|
—
est: 8.69M (-100.0%)
|
14.96M
14.96M – 14.96M
+72.2% YoY
|
26.49M
26.49M – 26.49M
+77.0% YoY
|
48.95M
48.95M – 48.95M
+84.8% YoY
|
267.34M
267.34M – 267.34M
+446.2% YoY
|
| EBITDA |
-14.38M
|
-25.79M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-14.87M
|
-26.34M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-14.20M
est: -10.45M (-35.9%)
|
-26.18M
est: -27.22M (+3.8%)
|
-6.19M
-6.19M – -6.19M
+77.3% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
—
— – —
|
| SGA |
9.31M
|
12.01M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-12.49
est: -3.18 (-292.6%)
|
-8.11
est: -8.28 (+2.1%)
|
-1.88
-1.88 – -1.88
+77.3% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
No beneficial ownership filings recorded.
Institutional Activity (13F)
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ADVISORSHARES INVESTMENTS LLC | 108.6K +59.0K (+118.8%) | 524.5K +162.2K (+44.8%) | 3.30% +1.794 pp | 0.10% +0.035 pp | USD4.79 +0.8% | 7 qtrs — |
| 2 | PLATFORM TECHNOLOGY PARTNERS | 41.1K +41.1K (+100.0%) | 198.6K +198.6K (+100.0%) | 1.25% +1.251 pp | 0.04% +0.038 pp | USD4.83 +0.0% | 1 qtrs NEW |
| 3 | UBS GROUP AG | 7.2K +5.5K (+323.2%) | 35.0K +22.5K (+180.0%) | 0.22% +0.168 pp | 0.00% +0.000 pp | USD8.37 -42.3% | 5 qtrs — |
| 4 | FARTHER FINANCE ADVISORS, LLC | 1.0K +— (+0.0%) | 4.4K -2.9K (-39.6%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD7.30 -33.8% | 2 qtrs — |
| 5 | SBI SECURITIES CO., LTD. | 75.00 +20.0 (+36.4%) | 362.00 -40.0 (-10.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD5.04 -4.2% | 6 qtrs — |
| 6 | ACTIVEST WEALTH MANAGEMENT | 15.00 +— (+0.0%) | 72.00 -38.0 (-34.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD7.67 -37.0% | 5 qtrs — |
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | AdvisorShares Psychedelics ETF PSIL | 1.74% | 773.0K | 1.84% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Donal Carroll | Chief Financial Officer | 429.4K | male |
| Anthony John Durkacz | Co-Founder & Executive Non-Independent Co-Chairman | 429.4K | male |
| Zeeshan Saeed | Co-Founder, Chief Executive Officer, & Executive Non-Independent Co-Chairman | 429.4K | male |
| Andrzej Chruscinski | Vice President of Clinical & Scientific Affairs | 162.8K | — |
| Kevin Cassidy | Vice President of Quality-Lucid | 144.8K | male |
| Ashwini Joshi | Director of Pharmaceutical Development | 113.6K | — |
| Nathan Coyle | Controller | 92.1K | male |
| Maryann Adesso | Corporate Secretary | — | female |
| Jason D. Sawyer | Head of Finance & Mergers and Acquisitions | — | male |
| Patrick Onyango | Director of Operations at U.S. | — | — |
| Randell Mack | President of FSD BioSciences | — | — |
| Lakshmi Kotra | President & Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for QNTM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
